A C Collier

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
  2. pmc Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy
    Christina M Marra
    Harborview Medical Center, University of Washington, Seattle, WA, USA
    BMC Infect Dis 7:37. 2007
  3. pmc A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
  4. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  5. ncbi request reprint A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
    J Infect Dis 192:1398-406. 2005
  6. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008
  7. ncbi request reprint Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial
    A C Collier
    School of Medicine, University of Washington, Seattle, WA 98104, USA
    JAMA 285:1592-601. 2001
  8. doi request reprint Neurocognitive impairment in HIV-infected individuals with previous syphilis
    C M Marra
    Department of Neurology, University of Washington, Seattle, WA, USA
    Int J STD AIDS 24:351-5. 2013
  9. ncbi request reprint Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS
    M M Berrey
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Infect Dis 183:1466-75. 2001
  10. ncbi request reprint Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood
    R W Coombs
    Department of Laboratory Medicine, University of Washington, School of Medicine, Seattle 98195 7110, USA
    J Infect Dis 177:320-30. 1998

Research Grants

  1. UW Clinical HIV Integrated Research Program
    Ann Collier; Fiscal Year: 2007

Detail Information

Publications52

  1. ncbi request reprint Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
    ..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
  2. pmc Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy
    Christina M Marra
    Harborview Medical Center, University of Washington, Seattle, WA, USA
    BMC Infect Dis 7:37. 2007
    ....
  3. pmc A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
    ..The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss...
  4. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  5. ncbi request reprint A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
    J Infect Dis 192:1398-406. 2005
    ..Adherence to antiretroviral therapy is difficult, and methods to increase it are needed...
  6. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008
    ....
  7. ncbi request reprint Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial
    A C Collier
    School of Medicine, University of Washington, Seattle, WA 98104, USA
    JAMA 285:1592-601. 2001
    ..Data in selected non-HIV-infected patients requiring blood transfusion have suggested clinical benefit with leukocyte-reduced red blood cells (RBCs)...
  8. doi request reprint Neurocognitive impairment in HIV-infected individuals with previous syphilis
    C M Marra
    Department of Neurology, University of Washington, Seattle, WA, USA
    Int J STD AIDS 24:351-5. 2013
    ..46] versus 0.31 [0.33], P = 0.03), and more were impaired in the NP learning domain (36 [42.9%] of 84 versus 13 [25.0%] of 52, P = 0.04). These effects of prior syphilis remained after controlling for education and premorbid intelligence...
  9. ncbi request reprint Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS
    M M Berrey
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Infect Dis 183:1466-75. 2001
    ..Combination antiretroviral therapy during primary HIV-1 infection demonstrated a decreased frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and reduced progression to AIDS...
  10. ncbi request reprint Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood
    R W Coombs
    Department of Laboratory Medicine, University of Washington, School of Medicine, Seattle 98195 7110, USA
    J Infect Dis 177:320-30. 1998
    ....
  11. ncbi request reprint Why don't patients and physicians talk about end-of-life care? Barriers to communication for patients with acquired immunodeficiency syndrome and their primary care clinicians
    J R Curtis
    Department of Medicine, University of Washington, Seattle 98104 2499, USA
    Arch Intern Med 160:1690-6. 2000
    ..Interventions to improve this communication have generally been unsuccessful, suggesting that important barriers to this communication must exist...
  12. pmc Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy
    C M Marra
    Department of Neurology, School of Medicine, University of Washington, Seattle, USA
    Neurology 60:1388-90. 2003
    ..001 and p = 0.02), and those treated with zidovudine or indinavir had greater improvement in NPZ-4 at both visits compared to those treated with other drugs (p = 0.003 and p = 0.01)...
  13. pmc Low atazanavir concentrations in cerebrospinal fluid
    Brookie M Best
    Skaggs School of Pharmacy andPharmaceutical Sciences, School of Medicine, Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, MC 0719, La Jolla, CA 92093 0719, USA
    AIDS 23:83-7. 2009
    ..The objective of this study was to determine atazanavir penetration into cerebrospinal fluid (CSF)...
  14. pmc Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group
    J D Stekler
    Department of Medicine, University of Washington, Seattle, WA, USA
    Int J STD AIDS 23:201-6. 2012
    ..Randomized trials are needed to address benefits of cART during PHI...
  15. ncbi request reprint A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group)
    J M Agosti
    Department of Medicine, University of Washington, Seattle
    AIDS Res Hum Retroviruses 8:581-7. 1992
    ..These cytokines alone do not appear to be of benefit, nor do they appear to hasten the progression of HIV infection...
  16. ncbi request reprint Cerebrospinal fluid treponemal antibodies in untreated early syphilis
    C M Marra
    Department of Medicine, University of Washington, Seattle
    Arch Neurol 52:68-72. 1995
    ..Nonreactive CSF treponemal tests may help to exclude a diagnosis of neurosyphilis in patients with early syphilis...
  17. ncbi request reprint Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex
    A C Collier
    Department of Medicine, University of Washington, Seattle, USA
    J Acquir Immune Defic Syndr Hum Retrovirol 10:150-6. 1995
    ..Additional studies that achieve higher CD4-IgG concentrations are necessary to evaluate the antiviral activity of this compound...
  18. pmc Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 50:1267-75. 2009
    ..Here we extend the initial noncompartmental analysis of these data and apply compartmental modeling to these human verapamil imaging studies...
  19. ncbi request reprint Primary HIV infection education: knowledge and attitudes of HIV-negative men who have sex with men attending a public health sexually transmitted disease clinic
    Joanne Stekler
    Division of Allergy and Infectious Diseases and Center for AIDS Research, University of Washington, Seattle, WA 98104, USA
    J Acquir Immune Defic Syndr 42:123-6. 2006
    ..Until more individuals with PHI seek evaluation, the public health impact of RNA testing is likely to be small...
  20. ncbi request reprint Abacavir hypersensitivity reaction in primary HIV infection
    Joanne Stekler
    Division of Allergy and Infectious Diseases, University of Washington, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104, USA
    AIDS 20:1269-74. 2006
    ..To evaluate risk factors associated with the abacavir hypersensitivity reaction during primary HIV infection (PHI)...
  21. ncbi request reprint Screening for acute HIV infection: lessons learned
    Joanne Stekler
    Department of Medicine, University of Washington, Seattle, WA, USA
    Clin Infect Dis 44:459-61. 2007
    ..We present cases to illustrate unusual instances of acute HIV screening, which include "window period" testing and the discovery of low-level HIV RNA...
  22. ncbi request reprint Primary HIV Infection
    Joanne Stekler
    Department of Medicine, Harborview Medical Center, Seattle, WA 98104, USA
    Curr HIV/AIDS Rep 1:68-73. 2004
    ..Immunomodulators and vaccines are also under study as adjuvant therapy for treatment of primary HIV infection...
  23. pmc HIV dynamics in seminal plasma during primary HIV infection
    Joanne Stekler
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    AIDS Res Hum Retroviruses 24:1269-74. 2008
    ..Incorporating seminal plasma HIV levels into future mathematical models may increase the accuracy of these models...
  24. pmc Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasma
    Jashvant D Unadkat
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Nucl Med Biol 35:911-7. 2008
    ..Therefore, we developed a rapid solid-phase extraction (SPE) method to separate, and then quantify, verapamil and its radiolabeled metabolites in plasma...
  25. pmc Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses
    Yi Liu
    Department of Microbiology, University of Washington School of Medicine, Seattle, Washington 98195 8070, USA
    J Infect Dis 200:1825-33. 2009
    ..However, some studies have shown preferential or similar targeting of variable versus conserved epitopes during primary infection...
  26. pmc Effect of early versus deferred antiretroviral therapy for HIV on survival
    Mari M Kitahata
    University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
    N Engl J Med 360:1815-26. 2009
    ..The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain...
  27. ncbi request reprint Lower genitourinary tract sources of seminal HIV
    Robert W Coombs
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104 2499, USA
    J Acquir Immune Defic Syndr 41:430-8. 2006
    ..To investigate genital tract sources of HIV-1, we conducted extensive genitourinary sampling of 23 seropositive men without urethritis who shed HIV in their seminal plasma...
  28. ncbi request reprint Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease
    Uma Malhotra
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA
    J Infect Dis 189:515-9. 2004
    ..These findings indicate that Fas coexpression on T cells, in addition to plasma HIV-1 RNA levels and CD4+ T cell counts, may predict virologic outcome...
  29. ncbi request reprint Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography
    Lucy Sasongko
    Department of Pharmaceutics, Division of Nuclear Medicine, University of Washington, Seattle, WA 98195 7610, USA
    Clin Pharmacol Ther 77:503-14. 2005
    ....
  30. ncbi request reprint Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data
    Peng Hsiao
    School of Pharmacy, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    J Pharmacol Exp Ther 317:704-10. 2006
    ..This is the first time that an in vivo CsA EC(50) of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration...
  31. pmc Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype
    Warren L Dinges
    Vaccine and Infectious Disease Institute, Statistical Center for HIV Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Virol 84:4461-8. 2010
    ..These data suggest that vaccine immunogens should contain only conserved regions of HIV-1...
  32. ncbi request reprint The attitudes of patients with advanced AIDS toward use of the medical futility rationale in decisions to forego mechanical ventilation
    J R Curtis
    Department of Medicine, University of Washington, Seattle, USA
    Arch Intern Med 160:1597-601. 2000
    ..The medical futility rationale asserts that physicians need not offer their patients therapies that have zero or close to zero probability of success. The rationale is controversial, but it is used in practice...
  33. pmc Selection on the human immunodeficiency virus type 1 proteome following primary infection
    Yi Liu
    Department of Microbiology, University of Washington School of Medicine, Seattle, WA 98195 8070, USA
    J Virol 80:9519-29. 2006
    ..Hence, a majority of the amino acids undergoing selection in this subject appeared to result from fitness-balanced CTL selection, confirming CTLs as a dominant selective force in HIV-1 infection...
  34. pmc Evaluation of cerebrospinal fluid in Southeast Asian refugees with reactive serologic tests for syphilis
    D Buchwald
    Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, Seattle, USA
    West J Med 165:289-93. 1996
    ....
  35. ncbi request reprint Abnormal antibody responses in patients with persistent generalized lymphadenopathy
    H D Ochs
    Department of Pediatrics, School of Medicine, University of Washington, Seattle 98195
    J Clin Immunol 8:57-63. 1988
    ..Yet despite obvious immunologic impairment five of the seven men have remained clinically stable over a 3-year follow-up period...
  36. pmc Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses
    Yi Liu
    Department of Microbiology, University of Washington School of Medicine, Seattle, Washington 98195 8070, USA
    Virology 374:229-33. 2008
    ....
  37. ncbi request reprint A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
    Margaret A Fischl
    Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
    J Infect Dis 188:625-34. 2003
    ..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity...
  38. pmc Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection
    Andrew J Leigh Brown
    University of Edinburgh, Edinburgh, Scotland
    J Virol 78:2242-6. 2004
    ..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection...
  39. pmc AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics
    Marlene Smurzynski
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    HIV Clin Trials 9:269-82. 2008
    ..We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy...
  40. ncbi request reprint Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
    Craig W Hendrix
    Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 37:1253-62. 2004
    ..Overall, however, the average change in viral load across all patients was +0.03 log10 HIV RNA. Given these results, AMD3100 is not being further developed for ARV therapy, but development continues for stem cell mobilization...
  41. ncbi request reprint Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
    Angela Dm Kashuba
    School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    AIDS 19:145-52. 2005
    ..To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment-experienced patients. Lack of drug interaction data prompted a pharmacokinetic substudy to minimize subject risk...
  42. ncbi request reprint Clinical validation of the NeuroScreen
    Ronald J Ellis
    Department of Neurosciences, UCSD AntiViral Research Center and HIV Neurobehavioral Research Center, University of California, San Diego, California 92103, USA
    J Neurovirol 11:503-11. 2005
    ..However, because it yields substantial numbers of false positives and negatives, the NeuroScreen may be less useful in evaluating individual patients...
  43. ncbi request reprint Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy
    Ronald J Bosch
    Center for Biostatistics in AIDS Research, Harvard University School of Public Health, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 44:268-77. 2007
    ..To examine pretreatment factors associated with longer term (144 weeks) responses to antiretroviral therapy (ART)...
  44. ncbi request reprint Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
    Margaret A Fischl
    AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
    AIDS 21:325-33. 2007
    ..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens...
  45. pmc Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance
    Lin Liu
    University of California San Diego, La Jolla, California 92093 0679, USA
    AIDS 22:835-9. 2008
    ..We compared eight genotypic interpretation methods to determine whether the method used would affect the rates of reported transmitted drug resistance...
  46. ncbi request reprint Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus
    Tae Wook Chun
    Laboratory of Immunoregulation, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 195:1762-4. 2007
    ..6 months. It is projected that it will take up to 7.7 years of continuous therapy to completely eliminate latently infected resting CD4+ T cells in infected individuals who initiate antiviral therapy early in HIV infection...
  47. ncbi request reprint Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)
    Pablo Tebas
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 45:193-200. 2007
    ..Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication...
  48. ncbi request reprint The prevalence and incidence of neurocognitive impairment in the HAART era
    Kevin R Robertson
    Department of Neurology, UNC, Chapel Hill, North Carolina 27599, USA
    AIDS 21:1915-21. 2007
    ..The effects of HAART on neurological disease are less well understood. The aim of this study was to assess the prevalence and incidence of neurocognitive impairment in individuals who initiated HAART as part of an AIDS clinical trial...
  49. pmc Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system
    Scott Letendre
    University of California, San Diego, 150 W Washington St, San Diego, CA 92103, USA
    Arch Neurol 65:65-70. 2008
    ..To evaluate whether penetration of a combination regimen into the central nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is associated with lower cerebrospinal fluid (CSF) viral load...
  50. ncbi request reprint Lack of interaction between atazanavir and lansoprazole
    Bradley W Kosel
    AIDS 19:637-8. 2005
  51. ncbi request reprint The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system
    Scott L Letendre
    University of California, 150 W Washington St, San Diego, CA 92103, USA
    J Neuroimmune Pharmacol 2:120-7. 2007
    ..Some of these drugs, such as serotonin reuptake inhibitors (SRIs) and HMG-CoA reductase inhibitors (statins), may do so by reducing HIV replication in the CNS and are already widely used by HIV-infected individuals...
  52. ncbi request reprint Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age
    Philippe Vanhems
    Laboratoire d épidémiologie et de santé publique, and INSERM Unit 271, Faculte de Medecine, Universite Claude Bernard, et Hôpital Edouard Herriot, Lyon, France
    J Acquir Immune Defic Syndr 31:318-21. 2002
    ..52%, p=.01). Genital ulcerations were present only in cases of sexual exposure to HIV. Injecting drug users had or reported symptoms associated with the ARS less frequently than persons acquiring HIV via sexual transmission...

Research Grants2

  1. UW Clinical HIV Integrated Research Program
    Ann Collier; Fiscal Year: 2007
    ..administrative component: ..